首页> 外文期刊>Seminars in pediatric neurology >Targeting Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL): A Promising Therapeutic Strategy in Gliomas
【24h】

Targeting Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL): A Promising Therapeutic Strategy in Gliomas

机译:靶向肿瘤坏死因子相关的凋亡诱导配体(TRAIL):胶质瘤的有前途的治疗策略。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) has been increasingly studied for the treatment of gliomas. TRAIL has the ability to specifically target cancer cells, without any harmful effects on normal cells, and induces apoptosis by interacting with specific receptors. Nevertheless, resistance mechanisms to TRAIL may occur at different points in the signaling pathways of TRAIL-induced apoptosis. Various approaches have been developed to overcome TRAIL resistance. Here, we have reviewed the known molecular pathways by which TRAIL exerts anticancer activity, possible resistance mechanisms, ways to sensitize resistant cancer cells, and finally the current clinical successes or limitations of TRAIL-based therapies. (C) 2015 Elsevier Inc. All rights reserved.
机译:肿瘤坏死因子相关的凋亡诱导配体(TRAIL)已被越来越多地研究用于神经胶质瘤的治疗。 TRAIL具有特异性靶向癌细胞的能力,而对正常细胞没有任何有害影响,并通过与特定受体相互作用诱导凋亡。然而,对TRAIL的抗性机制可能发生在TRAIL诱导的细胞凋亡的信号传导途径中的不同点。已经开发出各种方法来克服TRAIL抗性。在这里,我们综述了TRAIL发挥抗癌活性的已知分子途径,可能的耐药机制,敏化耐药癌细胞的方式以及最终基于TRAIL的疗法的当前临床成功或局限性。 (C)2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号